Pelthos, Castle Creek merge to chase rare skin-disease therapy, with up to $300M in milestones
What's the deal? Pelthos TherapeuticsDealroom has a profile for this one. Try Dealroom → (NYSE American: PTHS) has agreed to merge with Castle Creek Biosciences, pairing Pelthos' commercial dermatology business with Castle Creek's late-stage cell and gene therapy pipeline. Castle Creek shareholders will receive 5.2 million Pelthos shares at closing — about 32.5% of the combined company — plus additional equity and up to $300 million in milestone payments tied to clinical, regulatory, and sales targets.
What's the endgame? The merger centres on D-Fi (dabocemagene autoficel), Castle Creek's investigational gene-modified cell therapy for dystrophic epidermolysis bullosa (DEB), a rare inherited skin disease linked to chronic wounds and a raised risk of squamous cell carcinoma. The therapy uses a patient's own dermal fibroblasts, modified to produce type VII collagen, and is injected into chronic wounds every other month. It has FDA Orphan Drug Designation and is in Phase 3 development.
Why the fit? Pelthos markets three FDA-approved dermatology products — ZELSUVMI for molluscum contagiosum, XEPI for impetigo, and XEGLYZE for head lice — and plans to use that commercial infrastructure to support a D-Fi launch. "D-Fi builds on our established strength in dermatology, especially within pediatric dermatology, which we believe will accelerate its launch and value in the marketplace," said Pelthos chief executive officer Scott Plesha.
The terms. The $300 million is contingent, not upfront, with payments depending on clinical and commercial milestones. Castle Creek holders may also receive up to 5.8 million more shares if D-Fi wins FDA approval by March 31, 2036, and 80% of net proceeds from any priority review voucher sale. A roughly $57.5 million PIPE financing is part of the deal.
What could go wrong? D-Fi remains investigational, and its value hinges on Phase 3 results, including $50 million tied to those endpoints. The DEB market already has a benchmark in Krystal Biotech's approved topical gene therapy VYJUVEK, so D-Fi must show meaningful benefit rather than rely on its gene-therapy label. The transaction is subject to Castle Creek stockholder approval, an effective Form S-4, HSR clearance, and completion of the PIPE.
Why now? The deal is expected to close by the end of the first quarter of 2027. The combined company will keep the Pelthos name and trade on the NYSE American under PTHS.
The signal: This is a milestone-heavy, strategic route to fund and commercialise a clinical-stage programme rather than a large upfront buyout. In a biotech deal market featuring bigger rare-disease acquisitions, it reflects how cash-conscious companies are structuring combinations around contingent payouts — leaving trial results, financing, and execution as the key uncertainties.
Read more: citybiz.co
Image credit: Generated with Gemini
